Nordic Nanovector has announced that its Nomination Committee has nominated Dr Karin Meyer for election as a Non-executive Director at the company’s Annual General Meeting.
The company also notes that Gisela Schwab, who has served as a Non-executive Director on the Board of Nordic Nanovector since March 2015 has, due to increased workload, responsibilities and competing priorities, decided not to stand for re-election at the upcoming AGM.
“On behalf of the Board, I would like to thank Gisela for five years of service during which she has made valuable contributions to the advancement of the company. I am delighted to welcome Karin, who brings extensive experience in key areas that will be invaluable with regards to the future development of the company,” says Jan H. Egberts, Chairman of Nordic Nanovector’s Board of Directors.
25 years of experience in the pharmaceutical/life sciences area
Karin Meyer, PhD, has been nominated for election as a Non-executive Director at the AGM. Dr Meyer has 25 years of experience in the pharmaceutical/life sciences area, holding senior management and operational roles in private and public/non-profit organisations. She is currently Chief Executive Officer of the Swedish Pharmaceutical Society and Chairman of the board of two of its subsidiaries – Läkemedelsakademin i Stockholm AB and SPhS Stockholm Congress AB.
She has spent more than 10 years working in senior roles within Contract Research Organisations (CROs), including PCG Clinical Services and Quintiles, and is the former Deputy General Director of Uppsala University Innovations, with responsibility for the commercialization of innovations from the University, as well as investments, management and exits of start-up companies.
Dr Meyer is currently a Director on the Boards of Smartfish AS, Uppsala Monitoring Centre/WHO Collaborating Centre, Kårhuset Pharmen AB and Chair of the Board of NEPI Foundation (Nätverk för Läkemedelsepidemiologi).